Ensysce Biosciences vs Lipocine
ENSC and LPCN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENSC and LPCN compare
Lipocine is the larger company, worth 1.7 times as much as Ensysce Biosciences ($14.1M against $8.1M).
Ensysce Biosciences grew revenue faster over the last twelve months (37.9% versus −13.4% for Lipocine).
Lipocine scores higher on the StockData Score (11 against 9 for Ensysce Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENSC | LPCN |
|---|---|---|
| Size and price | ||
| Market cap | $8.1M | $14.1M |
| Share price | $0.418 | $1.71 |
| Change, 1 year | −79.7% | −41.4% |
| Change, 5 years | −100.0% | −91.4% |
| Beta (5Y) | 2.59 | 0.66 |
| Employees | 8 | 14 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 3 | 3 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× (better) | 3.8× |
| P/B | 0.3× (better) | 0.7× |
| Fair value | $1.73 | $3.29 |
| Margin of safety | 75.8% (better) | 48.0% |
| Growth | ||
| Revenue growth (TTM) | 37.9% (better) | −13.4% |
| Revenue growth, 5Y average | 5.2% | – |
| Profitability | ||
| Operating margin | −1477% | −269% (better) |
| Net margin | – | −249% |
| Return on equity | – | −52.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −7157.6× | – |
| Current ratio | 8.02 | 11.36 (better) |
| Altman Z-score | −17.54 | −9.08 (better) |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −114% |
| Shareholder yield | 0.00% (better) | −114% |
| Ownership | ||
| Held by institutions | 4.7% | 36.2% |
| Held by insiders | 6.2% | 8.4% |
| Insider net buying, 12 months | $444K | $517K (better) |
| Short interest, % of float | 0.49% | 4.3% |
Go deeper
- ENSC stock overview
- ENSC income statement
- ENSC valuation and score
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.